Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
about
Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemiaOutcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.Improving outcomes for high-risk ALL: translating new discoveries into clinical care.A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors.
P2860
Q30396832-B45E99F8-3EAF-438D-B236-4F095EA3D01EQ33628794-44882994-C316-4839-A0D7-252EA45AF210Q36015007-07905F06-7E35-447B-9EF4-46BF19D3EFF6Q37124911-9A9235D5-6410-44F9-8730-27D404CBAF25Q37126126-FBD5BDD9-FCE7-4FD3-83DB-1E558F102A17Q37166593-0669630E-FAD8-44ED-91C6-52E8452F7366Q37677743-1B6F013C-FAFC-47C5-BCBD-7056354AEF63Q37849259-7DA2FB97-AB31-417F-A4FF-B3F599E49571Q44103814-49399799-A1A2-43F9-AA08-441BA07AD354Q45051066-D17D8B1D-7428-4FCA-9895-93DC03A9467FQ48405212-D583FB88-118B-4BD0-A2D4-A092AB7AB0DF
P2860
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@en
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@nl
type
label
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@en
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@nl
prefLabel
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@en
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@nl
P2093
P2860
P1476
Comparison of idarubicin to da ...... m the Children's Cancer Group.
@en
P2093
Pendergrass TW
Steinherz L
P2860
P304
P356
10.1002/(SICI)1096-911X(199612)27:6<505::AID-MPO1>3.0.CO;2-P
P577
1996-12-01T00:00:00Z